Table 2.

Median (5th–95th percentile) concentrations of genistein^a among controls by country and study phase

Genistein (ng/ml)	Denmark	Germany	Greece	Italy	Netherlands	Spain	Sweden	UK	Total
Phase 1
Number	288	201	9	62	25	93	186	178	1,042
Median (5–95 percentile)	2.0 (0.05–23.8)	2.2 (0.05–23.5)	0.05 (0.05–17.2)	1.3 (0.05–10.3)	4.6 (0.2–40.1)	1.2 (0.05–7.4)	1.1 (0.05–14.9)	5.4 (0.2–41.5)	2.1 (0.05–24.5)
Phase 2
Number	0	211	31	84	25	108	0	196	655
Median (5–95 percentile)	–	1.6 (0.1–13.7)	0.3 (0.05–5.0)	1.1 (0.05–5.7)	6.5 (1.5–26.2)	1.0 (0.05–4.9)	–	3.1 (0.1–24.0)	1.7 (0.05–16.1)
Total
Number	288	412	40	146	50	201	186	374	1,697
Median (5–95 percentile)	2.0 (0.05–23.8)	1.9 (0.05–21)	0.3 (0.05–5.05)	1.15 (0.05–6.9)	5.2 (0.3–27.9)	1.2 (0.05–5.4)	1.1 (0.05–14.9)	4.3 (0.2–30.1)	1.9 (0.05–21.6)

^aFor participants with undetectable genistein levels, data were imputed at 0.05 ng/ml, half the lower limit of detection